

Wyeth

DATE October 23, 2009

Re: **IMPORTANT PRODUCT SUPPLY INFORMATION**

**Antivenin (Micrurus fulvius) (Equine Origin)
North American Coral Snake Antivenin**

**FURTHER EXTENSION OF EXPIRATION DATING TO OCTOBER 31, 2010
LOT NO. 4030026**

Dear Health Care Provider:

As you know, Wyeth is the license holder for the product North American Coral Snake Antivenin (Micrurus fulvius) (Equine). On October 15, 2009, Pfizer Inc. completed its acquisition of Wyeth. Accordingly, Wyeth is now a wholly owned subsidiary of Pfizer Inc. To learn more, please visit www.pfizer.com. All future communications to you regarding North American Coral Snake Antivenin (Micrurus fulvius) (Equine) will come from Pfizer Inc.

Pfizer Inc. would like to provide you with updated and very important information regarding Antivenin (Micrurus fulvius) (Equine Origin) North American Coral Snake Antivenin.

Last October, we announced the extension of the expiration date of one lot of Antivenin, Lot No. 4030026, until October 31, 2009, an additional 12 months beyond the labeled expiration date of October 31, 2008.

Pfizer Inc., working closely with the U.S. Food and Drug Administration (FDA), is extending the expiration date of Lot No. 4030026 for an additional 12 months. We have stability data that indicate that product from Lot No. 4030026 continues to be within applicable release specifications. **As a result, product from this lot will now be deemed to expire on October 31, 2010.**


As you may know, Pfizer Inc. no longer manufactures Antivenin, and there is currently no alternative FDA-approved supplier of this product. **Accordingly, it is imperative that you do not discard any product you have in your inventory of Lot No. 4030026. Please continue to maintain this product in your inventory and keep it available for use until October 31, 2010.**

Pfizer Inc. is carefully managing Antivenin (Micrurus fulvius) inventories and will supply product only to direct customers.

Antivenin (Micrurus fulvius) (Equine Origin) is indicated for the treatment of envenomation caused by the bites of M. f. fulvius (eastern coral snake) and M. f. teneris (Texas coral snake). Please see accompanying full Prescribing Information for indications and usage, dosage and administration, and important safety information. Also, the product Prescribing Information can be accessed by going to www.pfizer.com and clicking on the link to Wyeth Prescription Products.

If you have any questions, please call our Customer Service Department at 1-800-666-7248.

Sincerely,



Joseph S Camardo, MD
Senior Vice President
Global Medical Affairs

cc: US FDA